Relapsed Refractory Myeloma — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — A BCMA-directed cellular or bispecific-antibody therapy
The best answer is “A BCMA-directed cellular or bispecific-antibody therapy”. BCMA is highly expressed on plasma cells and can be targeted by CAR-T products or bispecific antibodies in appropriately pretreated relapsed myeloma. Choice depends on access, fitness, disease tempo and risks such as cytokine-release syndrome, neurotoxicity and infection. Reusing an ineffective single agent or targeting unrelated EGFR or BCR-ABL pathways is not rational.
Reference: eviQ: Multiple myeloma: https://www.eviq.org.au/haematology-and-bmt/multiple-myeloma